Literature DB >> 14993616

Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family.

Cecilia Garlanda1, Federica Riva, Nadia Polentarutti, Chiara Buracchi, Marina Sironi, Maida De Bortoli, Marta Muzio, Raffaella Bergottini, Eugenio Scanziani, Annunciata Vecchi, Emilio Hirsch, Alberto Mantovani.   

Abstract

TIR8, also known as single Ig IL-1-related receptor, is a member of the IL-1 receptor/Toll-like receptor (TLR) superfamily, which acts as an intracellular decoy for components of the signaling pathway. Here we report that Tir8 has a unique pattern of expression, which includes mucosal tissues and dendritic cells (DC). Tir8-deficient DC showed increased cytokine production in response to TLR agonists (lipopolysaccharide, CpG oligodeoxynucleotides). Tir8-deficient mice had normal susceptibility to systemic lipopolysaccharide toxicity and to i.p. or s.c. inflammation. However, Tir8-deficient mice were more susceptible to intestinal inflammation. Thus, TIR8 represents a negative pathway of regulation of the IL-1 receptor/TLR system, expressed in epithelial cells and DC, crucial for tuning inflammation in the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14993616      PMCID: PMC373495          DOI: 10.1073/pnas.0308680101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells.

Authors:  A Vecchi; L Massimiliano; S Ramponi; W Luini; S Bernasconi; R Bonecchi; P Allavena; M Parmentier; A Mantovani; S Sozzani
Journal:  J Leukoc Biol       Date:  1999-09       Impact factor: 4.962

2.  The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense.

Authors:  L A O'Neill; C A Dinarello
Journal:  Immunol Today       Date:  2000-05

Review 3.  Toll-like receptors and innate immunity.

Authors:  R Medzhitov
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

Review 4.  Endothelial cell dysfunction and coagulation.

Authors:  B Vallet; E Wiel
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

Review 5.  Macrophage migration inhibitory factor and innate immune responses to bacterial infections.

Authors:  C Froidevaux; T Roger; C Martin; M P Glauser; T Calandra
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

Review 6.  Mouse and human dendritic cell subtypes.

Authors:  Ken Shortman; Yong-Jun Liu
Journal:  Nat Rev Immunol       Date:  2002-03       Impact factor: 53.106

7.  Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production.

Authors:  B Siegmund; G Fantuzzi; F Rieder; F Gamboni-Robertson; H A Lehr; G Hartmann; C A Dinarello; S Endres; A Eigler
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-10       Impact factor: 3.619

Review 8.  Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines.

Authors:  A Mantovani; M Locati; A Vecchi; S Sozzani; P Allavena
Journal:  Trends Immunol       Date:  2001-06       Impact factor: 16.687

9.  IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation.

Authors:  B Siegmund; H A Lehr; G Fantuzzi; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

10.  CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation.

Authors:  A Suzuki; T Hanada; K Mitsuyama; T Yoshida; S Kamizono; T Hoshino; M Kubo; A Yamashita; M Okabe; K Takeda; S Akira; S Matsumoto; A Toyonaga; M Sata; A Yoshimura
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

View more
  90 in total

Review 1.  Research progress on interleukin-33 and its roles in the central nervous system.

Authors:  Ping Han; Wen-Li Mi; Yan-Qing Wang
Journal:  Neurosci Bull       Date:  2011-10       Impact factor: 5.203

2.  Differential regulation of Toll-like receptor signalling in spleen and Peyer's patch dendritic cells.

Authors:  Julie M Davies; John MacSharry; Fergus Shanahan
Journal:  Immunology       Date:  2010-11       Impact factor: 7.397

Review 3.  Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.

Authors:  Aya M Westbrook; Akos Szakmary; Robert H Schiestl
Journal:  Mutat Res       Date:  2010-03-16       Impact factor: 2.433

4.  Evidence for a DC-specific inhibitory mechanism that depends on MyD88 and SIGIRR.

Authors:  S K Drexler; J Wales; E Andreakos; P Kong; A Davis; C Garlanda; A Mantovani; T Hussell; M Feldmann; B M J Foxwell
Journal:  Scand J Immunol       Date:  2010-06       Impact factor: 3.487

Review 5.  Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2.

Authors:  E Cario
Journal:  Gut       Date:  2005-04-19       Impact factor: 23.059

Review 6.  The gut flora as a forgotten organ.

Authors:  Ann M O'Hara; Fergus Shanahan
Journal:  EMBO Rep       Date:  2006-07       Impact factor: 8.807

Review 7.  Toll-like receptors and corneal innate immunity.

Authors:  Ashok Kumar; Fu-Shin X Yu
Journal:  Curr Mol Med       Date:  2006-05       Impact factor: 2.222

8.  Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis.

Authors:  Franak M Batliwalla; Wentian Li; Christopher T Ritchlin; Xiangli Xiao; Max Brenner; Teresina Laragione; Tianmeng Shao; Robert Durham; Sunil Kemshetti; Edward Schwarz; Rodney Coe; Marlena Kern; Emily C Baechler; Timothy W Behrens; Peter K Gregersen; Pércio S Gulko
Journal:  Mol Med       Date:  2005 Jan-Dec       Impact factor: 6.354

9.  The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response.

Authors:  Katarzyna Bulek; Shadi Swaidani; Jinzhong Qin; Yi Lu; Muhammet F Gulen; Tomasz Herjan; Booki Min; Robert A Kastelein; Mark Aronica; Magdalena Kosz-Vnenchak; Xiaoxia Li
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

10.  Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation.

Authors:  Giulio Cavalli; Marije Koenders; Vassili Kalabokis; Jihye Kim; Aik Choon Tan; Cecilia Garlanda; Alberto Mantovani; Lorenzo Dagna; Leo A B Joosten; Charles A Dinarello
Journal:  Rheumatology (Oxford)       Date:  2016-08-26       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.